Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner

OBJECTIVE: The objective of this study is to elucidate the effect of anagliptin on glucose/lipid metabolism and renoprotection in patients with type 2 diabetic nephropathy. METHODS: Twenty-five patients with type 2 diabetic nephropathy received anagliptin 200 mg/day for 24 weeks, and 20 patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitada, Munehiro, Tsuda, Shin-ichi, Konishi, Kazunori, Takeda-Watanabe, Ai, Fujii, Mizue, Kanasaki, Keizo, Nishizawa, Makoto, Nakagawa, Atsushi, Koya, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Open Diabetes Research & Care 2017
Materias:
Pathophysiology/Complications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530236/
https://www.ncbi.nlm.nih.gov/pubmed/28761658
http://dx.doi.org/10.1136/bmjdrc-2017-000391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530236/
https://www.ncbi.nlm.nih.gov/pubmed/28761658
http://dx.doi.org/10.1136/bmjdrc-2017-000391

Ejemplares similares